Version history

{
  "description": "Methodology challenge: dataset 'SEA-AD Differential Expression: AD vs Control (MTG)' — evaluate design, statistical methods, and reproducibility.\n\n[TARGET_ARTIFACT type=dataset id=tabular_dataset-b3889491-fc25-440e-863d-bc96f9d33c51]\n[DEBATE_TYPE methodology_challenge]\n[PERSONAS provenance_auditor,bias_detector,schema_validator]\n[NUM_ROUNDS 4]\n[AUTO_TRIGGER rule=notebook_debate_scheduler]",
  "domain": "neurodegeneration",
  "status": "resolved",
  "priority_score": 0.92,
  "estimated_effort": "medium",
  "evidence_summary": "Resolved by hypothesis h-5b378bd3: TREM2-APOE Axis Dissociation for Selective DAM Activation. Score: 0.886. Supporting PMIDs: 28930663, 30617257.",
  "resolution_criteria": "Resolved when the provenance_auditor persona certifies the SEA-AD Differential Expression: AD vs Control (MTG) dataset's RNA extraction protocol, sequencing method, and differential expression analysis pipeline. A passing assessment requires: (1) schema validation confirming metadata fields for donor demographics, PMI, Braak stage, CERAD score, APOE genotype, and brain region (MTG); (2) reproducibility audit confirming >=80% concordance between the dataset's published DE gene list and independently reanalyzed raw count data using the same thresholds (|logFC| > 0.5, FDR < 0.05); (3) statistical methods review confirming appropriate library size normalization (TMM or similar), batch effect correction (ComBat or removeBatchEffect), and consensus DE gene calls across >=2 biological contrast groups. The bias_detector persona must flag any confounding variables (age, sex, PMI) before closure.",
  "market_price": 0.5
}